Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18564552 | 0.99 | MEN1 (0.35) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL18564496 | 0.99 | KDM4E (0.36) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL18564528 | 0.98 | KDM4E (0.35) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL18564545 | 0.96 | KDM4E (0.35) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL22192269 | 0.96 | KDM4E (0.40) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL22192746 | 0.96 | KDM4E (0.40) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL18564570 | 0.96 | KDM4E (0.36) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL15257557 | 0.95 | KDM4E (0.38) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL22192435 | 0.94 | KDM4E (0.38) | KDM4EL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL22192292 | 0.94 | KDM4E (0.38) | KDM4EL3MBTL1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10290815-B2 | Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-02 | — | — | US | disclosed |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10290815-B2 | Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device | EED, BMI1, CD99 | KDM4E 225/4885L3MBTL1 1263/4885ATM 3092/4885 |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | EED, BMI1, CD99 | KDM4E 225/4885L3MBTL1 1263/4885ATM 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.